- Home
- BDRX vs SLRX Comparison
BDRX vs SLRX Comparison
Compare BDRX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- SLRX
- Stock Information
- Founded
- BDRX 2000
- SLRX N/A
- Country
- BDRX United Kingdom
- SLRX United States
- Employees
- BDRX 13
- SLRX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- SLRX Health Care
- Exchange
- BDRX Nasdaq
- SLRX Nasdaq
- Market Cap
- BDRX 3.9M
- SLRX 2.9M
- IPO Year
- BDRX N/A
- SLRX N/A
- Fundamental
- Price
- BDRX $6.80
- SLRX $5.56
- Analyst Decision
- BDRX
- SLRX
- Analyst Count
- BDRX 0
- SLRX 0
- Target Price
- BDRX N/A
- SLRX N/A
- AVG Volume (30 Days)
- BDRX 53.1K
- SLRX 286.4K
- Earning Date
- BDRX 09-23-2025
- SLRX 11-13-2025
- Dividend Yield
- BDRX N/A
- SLRX N/A
- EPS Growth
- BDRX N/A
- SLRX N/A
- EPS
- BDRX N/A
- SLRX N/A
- Revenue
- BDRX N/A
- SLRX N/A
- Revenue This Year
- BDRX N/A
- SLRX N/A
- Revenue Next Year
- BDRX N/A
- SLRX N/A
- P/E Ratio
- BDRX N/A
- SLRX N/A
- Revenue Growth
- BDRX N/A
- SLRX N/A
- 52 Week Low
- BDRX $5.00
- SLRX $4.50
- 52 Week High
- BDRX $108.90
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- BDRX 57.44
- SLRX 43.47
- Support Level
- BDRX $5.81
- SLRX $4.79
- Resistance Level
- BDRX $6.47
- SLRX $5.90
- Average True Range (ATR)
- BDRX 0.50
- SLRX 0.40
- MACD
- BDRX 0.20
- SLRX 0.27
- Stochastic Oscillator
- BDRX 97.30
- SLRX 75.36
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.